Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 flgt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of
EX-99.1 2 flgt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% • GAAP loss of $29.5 million, or $(1.05) per share; Non-GAAP loss of $16.2 million, or $(0.58) per share • Executed on stock repurchase program; purchased approximately 1.5 million shares in the second quarter of 2026 totaling $23.8 million in cash • Ended the second quarter of 2026 with $551.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.1 million • Revised annual revenue guidance to be in the range of $330.0-$340.0 million EL MONTE, CA, July 30, 2026 — Fulgent Genetics, Inc. (NAS...
Source
Exhibit EX-99.1
0001193125-26-326119
Filed July 30, 2026 at 8:09 PM UTC. The figures above are from the audited statements, not from this release.